Cargando…
Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma
The computational repositioning of existing drugs represents an appealing avenue for identifying effective compounds to treat diseases with no FDA-approved pharmacotherapies. Here we present the largest meta-analysis to date of differential gene expression in human vestibular schwannoma (VS), a debi...
Autores principales: | Sagers, Jessica E., Brown, Adam S., Vasilijic, Sasa, Lewis, Rebecca M., Sahin, Mehmet I., Landegger, Lukas D., Perlis, Roy H., Kohane, Isaac S., Welling, D. Bradley, Patel, Chirag J., Stankovic, Konstantina M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882888/ https://www.ncbi.nlm.nih.gov/pubmed/29615643 http://dx.doi.org/10.1038/s41598-018-23609-7 |
Ejemplares similares
-
Publisher Correction: Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma
por: Sagers, Jessica E., et al.
Publicado: (2018) -
Identification of Immune-Related Candidate Biomarkers in Plasma of Patients with Sporadic Vestibular Schwannoma: Candidate Plasma Biomarkers in Vestibular Schwannoma
por: Vasilijic, Sasa, et al.
Publicado: (2023) -
Identification of immune-related candidate biomarkers in plasma of patients with sporadic vestibular schwannoma
por: Vasilijic, Sasa, et al.
Publicado: (2023) -
New developments in neurofibromatosis type 2 and vestibular schwannoma
por: Ren, Yin, et al.
Publicado: (2020) -
MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas
por: Ren, Yin, et al.
Publicado: (2020)